Value based healthcare: the implications for pharma strategy

Complete the registration form opposite to download a copy of Value based healthcare: the implications for pharma strategy

Entitled Value-based healthcare: The impact on pharma strategy, the report argues that for many pharma companies, VBH has often seemed like an attack on their business model. Payers seek to ensure that prices correlate with outcome. In their search for the most cost-effective treatments, many countries now use health technology assessments (HTA) to decide on reimbursement. This is seen by many as yet another hoop that pharma companies have to jump through to sell their drugs, raising the risk that their investment in R&D will not pay off

Download: Value based healthcare: the implications for pharma strategy

The Economist Intelligence Unit helps business leaders prepare for opportunity, empowering them to act with confidence when making strategic decisions. We are renowned for our comprehensive global coverage and use the best analytical minds to examine markets, countries and industries with a level of insight you cannot find elsewhere. Uncompromising integrity, relentless rigour and precise communication underpin everything we do. We are meticulous with every analysis, every study, every projection and every commentary that carries the EIU brand. Our reputation for trusted business intelligence depends on it. Crystallise your thinking and see greater possibilities with business intelligence from the EIU–the most assured way to prepare for opportunity.